Hepatic Angiomyolipoma in Patients With Inflammatory Breast Cancer: A Case Report

TL;DR

A rare case of a patient with inflammatory breast cancer and a hepatic angiomyolipoma is reported, highlighting the challenges in diagnosis and treatment.

Contribution

This case report adds to the limited literature on the coexistence of hepatic angiomyolipoma and inflammatory breast cancer.

Findings

A 63-year-old female patient was diagnosed with both inflammatory breast cancer and hepatic angiomyolipoma.

The patient underwent successful modified radical mastectomy and liver resection with ongoing follow-up.

Multidisciplinary approaches are essential for managing patients with coexisting HAML and IBC.

Abstract

Hepatic angiomyolipoma (HAML) is a rare tumor comprising adipose tissue, smooth muscle cells, and blood vessels. On the other hand, inflammatory breast cancer (IBC) is a rare and severe form of breast cancer that progresses quickly and presents as breast inflammation. It is incredibly unusual for HAML and IBC to coexist in the same patient. In the present study, we describe a case of a 63-year-old Yemeni female patient diagnosed with locally advanced left breast cancer presented with pain at the left breast and axilla. A computed tomography (CT) scan for staging showed an incidental large hepatic mass, which was eventually discovered to be HAML. The patient underwent a modified radical mastectomy after completing her neoadjuvant treatment and later underwent parenchyma-sparing liver resection of that lesion; follow-up has continued till now. The diagnosis of HAML in the presence of IBC can pose challenges due to overlapping clinical and radiological features. Treatment decisions for patients with coexisting HAML and IBC require a multidisciplinary approach; surgical resection, embolization, targeted therapies, and systemic chemotherapy may be considered based on the extent of the disease and individual patient factors. Lastly, a brief review of the related literature was also carried out.

Figures